Clinical Trial Update: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy, safety, and pharmacokinetics of FNP-223 to slow progression of Progressive supranuclear palsy; the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Supranuclear Palsy

Drugs mentioned

• FNP-223

Snippet

Sponsor: Ferrer Internacional S.A. | Conditions: Progressive Supranuclear Palsy | Phase 2 | Status: ACTIVE_NOT_RECRUITING